Weighted Average Number of Shares Outstanding, Diluted of Lexaria Bioscience Corp. from 31 Jul 2010 to 30 Nov 2025

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Lexaria Bioscience Corp. quarterly and annual Weighted Average Number of Shares Outstanding, Diluted in shares history and change rate from 31 Jul 2010 to 30 Nov 2025.
  • Lexaria Bioscience Corp. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 30 Nov 2025 was 21,376,029, a 28% increase year-over-year.
  • Lexaria Bioscience Corp. annual Weighted Average Number of Shares Outstanding, Diluted for 2025 was 17,998,715, a 45% increase from 2024.
  • Lexaria Bioscience Corp. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 12,383,974, a 87% increase from 2023.
  • Lexaria Bioscience Corp. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 6,614,066.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

Lexaria Bioscience Corp. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 21,376,029 +4,707,516 +28% 01 Sep 2025 30 Nov 2025 10-Q 13 Jan 2026 2026 Q1
Q3 2025 17,998,715 +5,614,741 +45% 01 Jun 2025 31 Aug 2025 10-K 28 Nov 2025 2025 FY
Q2 2025 18,298,309 +4,443,107 +32% 01 Mar 2025 31 May 2025 10-Q 14 Jul 2025 2025 Q3
Q1 2025 17,511,908 +6,746,765 +63% 01 Dec 2024 28 Feb 2025 10-Q 14 Apr 2025 2025 Q2
Q4 2024 16,668,513 +7,616,982 +84% 01 Sep 2024 30 Nov 2024 10-Q 13 Jan 2026 2026 Q1
Q3 2024 12,383,974 01 Jun 2024 31 Aug 2024 10-K 28 Nov 2025 2025 FY
Q2 2024 13,855,202 01 Mar 2024 31 May 2024 10-Q 14 Jul 2025 2025 Q3
Q1 2024 10,765,143 01 Dec 2023 29 Feb 2024 10-Q 14 Apr 2025 2025 Q2
Q4 2023 9,051,531 01 Sep 2023 30 Nov 2023 10-Q 10 Jan 2025 2025 Q1
Q2 2012 16,437,269 +2,160,493 +15% 01 May 2012 31 Jul 2012 10-Q 12 Sep 2012 2012 Q3
Q1 2012 16,431,452 +3,344,321 +26% 01 Feb 2012 30 Apr 2012 10-Q 07 Jun 2012 2012 Q2
Q4 2011 16,431,452 +3,451,531 +27% 01 Nov 2011 31 Jan 2012 10-Q 13 Mar 2012 2012 Q1
Q3 2011 14,176,503 01 Aug 2011 31 Oct 2011 10-K 30 Jan 2012 2011 FY
Q2 2011 14,276,776 +1,594,703 +13% 01 May 2011 31 Jul 2011 10-Q 12 Sep 2012 2012 Q3
Q1 2011 13,087,131 01 Feb 2011 30 Apr 2011 10-Q 07 Jun 2012 2012 Q2
Q4 2010 12,979,921 01 Nov 2010 31 Jan 2011 10-Q 13 Mar 2012 2012 Q1
Q2 2010 12,682,073 01 May 2010 31 Jul 2010 10-Q 14 Sep 2011 2011 Q3

Lexaria Bioscience Corp. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 17,998,715 +5,614,741 +45% 01 Sep 2024 31 Aug 2025 10-K 28 Nov 2025 2025 FY
2024 12,383,974 +5,769,908 +87% 01 Sep 2023 31 Aug 2024 10-K 28 Nov 2025 2025 FY
2023 6,614,066 01 Sep 2022 31 Aug 2023 10-K 26 Nov 2024 2024 FY
2011 14,176,503 +1,850,828 +15% 01 Nov 2010 31 Oct 2011 10-K 30 Jan 2012 2011 FY
2010 12,325,675 01 Nov 2009 31 Oct 2010 10-K 30 Jan 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.